Investor's Business Daily on MSN55m
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.
Fourth-quarter earnings at JPMorgan Chase, Wells Fargo, Goldman Sachs, and Citigroup beat analysts’ estimates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback